Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis

Abstract

Etanercept is a dimeric fusion protein based on the p75 TNF-α receptor. It binds to TNF-α and blocks its biologic activity. In randomized, double-blind, placebo-controlled trials, etanercept has therapeutic activity in rheumatoid arthritis, psoriatic arthritis, polyarticular-course juvenile idiophatic arthritis and ankylosing spondylitis. Etanercept improves joint inflammation, physical function and slows/halts structural damage, especially when combined with methotrexate. A sustained response is observed in a substantial percentage of patients. Although some safety issues should be considered before starting etanercept treatment, in general terms, etanercept is a well tolerated drug with an acceptable safety profile. The use of any TNF-α antagonist must be in agreement with the National Recommendations for Biologic Therapy, and in difficult clinical situations, a balance between risk/benefit needs to be obtained.

Keywords::

• ankylosing spondylitis
• clinical trial
• efficacy
• etanercept
• juvenile idiopathic arthritis
• methotrexate
• psoriatic arthritis
• rheumatoid arthritis
• safety

Notes